180 Life Sciences Corp.

KBL Merger Corp. IV (Nasdaq: KBLM) was a blank-check company sponsored by KBL Healthcare Acquisitions that completed a business combination with 180 Life Sciences Corp., a clinical-stage biotechnology and medical device company focused on the treatment of inflammatory diseases. The SPAC went public in 2019 and targeted the healthcare and medtech sector. The merger was announced in September 2020, and the transaction has since closed, with 180 Life Sciences continuing as the surviving public entity. For comprehensive filing histories, deal timelines, and institutional-grade data on KBLM and hundreds of other SPACs, sign up for full access at SpacDesk.

SPAC Counterparty (1)